Hsiang‐i Tsai

1.3k total citations · 1 hit paper
32 papers, 964 citations indexed

About

Hsiang‐i Tsai is a scholar working on Molecular Biology, Oncology and Biomaterials. According to data from OpenAlex, Hsiang‐i Tsai has authored 32 papers receiving a total of 964 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 7 papers in Oncology and 7 papers in Biomaterials. Recurrent topics in Hsiang‐i Tsai's work include Nanoparticle-Based Drug Delivery (7 papers), Epigenetics and DNA Methylation (5 papers) and RNA modifications and cancer (5 papers). Hsiang‐i Tsai is often cited by papers focused on Nanoparticle-Based Drug Delivery (7 papers), Epigenetics and DNA Methylation (5 papers) and RNA modifications and cancer (5 papers). Hsiang‐i Tsai collaborates with scholars based in China, Canada and Finland. Hsiang‐i Tsai's co-authors include Haitao Zhu, Lin Mei, Zhanxue Xu, Hongbo Chen, Xiaowei Zeng, Gan Liu, Fang Cheng, Dongqing Wang, Laiqiang Huang and Wei Tao and has published in prestigious journals such as ACS Nano, ACS Applied Materials & Interfaces and Free Radical Biology and Medicine.

In The Last Decade

Hsiang‐i Tsai

29 papers receiving 959 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities

2024 44 citations Rong Yu, John Eriksson et al. Cancer Letters profile →

Peers

Countries citing papers authored by Hsiang‐i Tsai

Since Specialization

Citations

This map shows the geographic impact of Hsiang‐i Tsai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hsiang‐i Tsai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hsiang‐i Tsai more than expected).

Fields of papers citing papers by Hsiang‐i Tsai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hsiang‐i Tsai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hsiang‐i Tsai. The network helps show where Hsiang‐i Tsai may publish in the future.

Co-authorship network of co-authors of Hsiang‐i Tsai

This figure shows the co-authorship network connecting the top 25 collaborators of Hsiang‐i Tsai. A scholar is included among the top collaborators of Hsiang‐i Tsai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hsiang‐i Tsai. Hsiang‐i Tsai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cancer stem cells amino acid metabolism: Roles, mechanisms, and intervention strategies 2025 ·Cellular Signalling ·(unknown), Xirui Wang, Wenlong Chen, Hsiang‐i Tsai, Yanfang Liu	0
2	STING and metabolism-related diseases: Roles, mechanisms, and applications 2025 ·Cellular Signalling ·Zhengyang Zhang, Xirui Wang, (unknown), Haitao Zhu, (unknown), Hsiang‐i Tsai	0
3	CX-5461 ameliorates disease in lupus-prone mice by triggering B-cell ferroptosis via p53-SLC7A11-ALOX12 pathway 2024 ·Free Radical Biology and Medicine ·Yingyi Wu, Hsiang‐i Tsai, Huiming Zhu, (unknown), (unknown), Panpan Guo, (unknown), Zhengyang Zhang, (unknown), Dandan Wang, Lingyun Sun	6
4	Overcoming the limitations of immunotherapy in pancreatic ductal adenocarcinoma: Combining radiotherapy and metabolic targeting therapy 2024 ·Journal of Cancer ·Han Zhang, (unknown), Haitao Zhu, Xuelian Chen, Hsiang‐i Tsai	6
5	TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma 2024 ·Cancer Letters ·Linglu Wang, Xiaoyan Liu, (unknown), Hsiang‐i Tsai, (unknown), (unknown), Zhanxue Xu, (unknown), Chao He, John Eriksson, Haitao Zhu, Hongbo Chen, Fang Cheng	13
6	Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities breakdown → 2024 ·Cancer Letters ·(unknown), Rong Yu, John Eriksson, Hsiang‐i Tsai, Haitao Zhu	44
7	KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression 2023 ·Frontiers in Cell and Developmental Biology ·(unknown), Heng Zhang, (unknown), Hsiang‐i Tsai	32
8	Fe ³⁺ -binding transferrin nanovesicles encapsulating sorafenib induce ferroptosis in hepatocellular carcinoma 2023 ·Biomaterials Research ·(unknown), Zhanxue Xu, Yuan Cheng, (unknown), (unknown), Hsiang‐i Tsai, (unknown), (unknown), Kai Wang, (unknown), Yanfeng Gao, Changhua Zhang, Fang Cheng, Hongbo Chen	31
9	PD-1 Cellular Nanovesicles Carrying Gemcitabine to Inhibit the Proliferation of Triple Negative Breast Cancer Cell 2022 ·Pharmaceutics ·(unknown), Zhanxue Xu, (unknown), (unknown), (unknown), (unknown), Hsiang‐i Tsai, Dandan Su, Fang Cheng, (unknown), Hongbo Chen	6
10	PHF6 functions as a tumor suppressor by recruiting methyltransferase SUV39H1 to nucleolar region and offers a novel therapeutic target for PHF6-muntant leukemia 2021 ·Acta Pharmaceutica Sinica B ·Hsiang‐i Tsai, Yanping Wu, Rui Huang, Dandan Su, Yingyi Wu, Xiaoyan Liu, Linglu Wang, Zhanxue Xu, Yuxin Pang, Chong Sun, Chao He, (unknown), Haitao Zhu, Dongqing Wang, Fang Cheng, Laiqiang Huang, Hongbo Chen	10
11	NF45/NF90‐mediated rDNA transcription provides a novel target for immunosuppressant development 2021 ·EMBO Molecular Medicine ·Hsiang‐i Tsai, Xiaobin Zeng, Longshan Liu, (unknown), Yingyi Wu, Zhanxue Xu, Huanxi Zhang, Liu Gan, (unknown), Dandan Su, Min Yang, Yijing Tao, Changxi Wang, Jing Zhao, John Eriksson, Wenbin Deng, Fang Cheng, Hongbo Chen	7
12	Engineering Programmed Death Ligand-1/Cytotoxic T-Lymphocyte-Associated Antigen-4 Dual-Targeting Nanovesicles for Immunosuppressive Therapy in Transplantation 2020 ·ACS Nano ·Zhanxue Xu, Hsiang‐i Tsai, (unknown), Yingyi Wu, Dandan Su, Min Yang, (unknown), (unknown), Xiaoyan Liu, Fang Cheng, Hongbo Chen	45
13	PD-L1 cellular nanovesicles carrying rapamycin inhibit alloimmune responses in transplantation 2020 ·Biomaterials Science ·Min Yang, Zhanxue Xu, (unknown), Hsiang‐i Tsai, Dandan Su, (unknown), (unknown), (unknown), Weiwei Zeng, (unknown), (unknown), Yunzhi Ling, Chao He, Yingyi Wu, Xiaowei Xu, Zheng Gang, Gan Liu, Hongbo Chen, Fang Cheng	16
14	Branched-chain amino acid aminotransferase 2 regulates ferroptotic cell death in cancer cells 2020 ·Cell Death and Differentiation ·Kang Wang, Zhengyang Zhang, Hsiang‐i Tsai, Yanfang Liu, Jie Gao, Ming Wang, Song Lian, Xiongfeng Cao, Zhanxue Xu, Hongbo Chen, Aihua Gong, Dongqing Wang, Fang Cheng, Haitao Zhu	171
15	Wnt/β-Catenin Pathway-Regulated Fibromodulin Expression Is Crucial for Breast Cancer Metastasis and Inhibited by Aspirin 2019 ·Frontiers in Pharmacology ·Fahim Ullah Khan, (unknown), Xiaoyong Dai, Kewei Liu, Yanping Wu, Hsiang‐i Tsai, Hongbo Chen, Chunhui Sun, Laiqiang Huang	23
16	DACHPt-Loaded Nanoparticles Self-assembled from Biodegradable Dendritic Copolymer Polyglutamic Acid-b-D-α-Tocopheryl Polyethylene Glycol 1000 Succinate for Multidrug Resistant Lung Cancer Therapy 2018 ·Frontiers in Pharmacology ·Hsiang‐i Tsai, Lijuan Jiang, Xiaowei Zeng, Hongbo Chen, Zihuang Li, Wei Cheng, Jinxie Zhang, Jie Pan, Dong Wan, Li Gao, Zhenhua Xie, Laiqiang Huang, Lin Mei, Liu Gan	15
17	Phosphorylcholine-based stealthy nanocapsules enabling tumor microenvironment-responsive doxorubicin release for tumor suppression 2017 ·Theranostics ·Gan Liu, Hsiang‐i Tsai, Xiaowei Zeng, (unknown), Wei Tao, Jun Han, Lin Mei	47
18	Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy 2016 ·Oncotarget ·Tingting Feng, Wei Cao, Wan Xiang Shen, Liang Zhang, Xinsheng Gu, Yang Guo, Hsiang‐i Tsai, Xuewen Liu, Jian Li, Jingxuan Zhang, Shan Li, Fuyun Wu, Ying Liu	68
19	DACHPt-Loaded Unimolecular Micelles Based on Hydrophilic Dendritic Block Copolymers for Enhanced Therapy of Lung Cancer 2016 ·ACS Applied Materials & Interfaces ·Gan Liu, Hong‐Jun Gao, (unknown), Xiaowei Zeng, Wei Tao, Hsiang‐i Tsai, Lin Mei	42
20	The effects of quercetin-loaded PLGA-TPGS nanoparticles on ultraviolet B-induced skin damages in vivo 2015 ·Nanomedicine Nanotechnology Biology and Medicine ·Xianbing Zhu, Xiaowei Zeng, Xudong Zhang, Wei Cao, Yilin Wang, Houjie Chen, Teng Wang, Hsiang‐i Tsai, Ran Zhang, Danfeng Chang, Shuai He, Lin Mei, Xiaojun Shi	63

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact